- Home
- PLX vs NVX Comparison
PLX vs NVX Comparison
Compare PLX & NVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- NVX
- Stock Information
- Founded
- PLX 1993
- NVX 2012
- Country
- PLX United States
- NVX Australia
- Employees
- PLX N/A
- NVX N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- NVX Industrial Machinery/Components
- Sector
- PLX Health Care
- NVX Miscellaneous
- Exchange
- PLX Nasdaq
- NVX Nasdaq
- Market Cap
- PLX 204.9M
- NVX 204.1M
- IPO Year
- PLX 1998
- NVX N/A
- Fundamental
- Price
- PLX $2.19
- NVX $1.21
- Analyst Decision
- PLX Strong Buy
- NVX
- Analyst Count
- PLX 1
- NVX 0
- Target Price
- PLX $15.00
- NVX N/A
- AVG Volume (30 Days)
- PLX 934.1K
- NVX 6.7M
- Earning Date
- PLX 11-13-2025
- NVX 01-01-0001
- Dividend Yield
- PLX N/A
- NVX N/A
- EPS Growth
- PLX N/A
- NVX N/A
- EPS
- PLX 0.08
- NVX N/A
- Revenue
- PLX $61,948,000.00
- NVX $5,931,433.00
- Revenue This Year
- PLX $14.53
- NVX $165.90
- Revenue Next Year
- PLX $75.77
- NVX $1,344.85
- P/E Ratio
- PLX $28.28
- NVX N/A
- Revenue Growth
- PLX 62.79
- NVX N/A
- 52 Week Low
- PLX $1.16
- NVX $0.81
- 52 Week High
- PLX $3.10
- NVX $3.86
- Technical
- Relative Strength Index (RSI)
- PLX 46.99
- NVX 36.64
- Support Level
- PLX $2.25
- NVX $1.21
- Resistance Level
- PLX $2.40
- NVX $2.07
- Average True Range (ATR)
- PLX 0.14
- NVX 0.17
- MACD
- PLX -0.02
- NVX -0.10
- Stochastic Oscillator
- PLX 40.70
- NVX 6.00
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.